More people affected by memory diseases in aging society

As the population ages, more people are affected by memory diseases like Alzheimer's. However, research in the field is progressing slowly, and only about half of those affected receive the available treatment.

In an opinion piece in Dagens Nyheter, Lisa Magnusson questions how pleasant the final years of life will truly be for many elderly people. She notes that as lifespans increase, more individuals are affected by memory diseases. Despite this, research in the area is advancing slowly.

The article states that only about half of those suffering from Alzheimer's receive the treatment that is actually available. This raises concerns about how society addresses the rising prevalence of these conditions. Magnusson emphasizes the need for better support and progress in healthcare to ensure a dignified old age.

The piece was published on January 10, 2026, and is part of DN's editorial page, focusing on debate and reflection on societal issues.

Articoli correlati

Diverse young adults reviewing charts on rising cognitive disabilities in a community setting, illustrating a Neurology study on surges among under-40s due to social and economic factors.
Immagine generata dall'IA

Self-reported cognitive disabilities surge among young U.S. adults

Riportato dall'IA Immagine generata dall'IA Verificato

A peer-reviewed Neurology study finds a sharp rise in self-reported cognitive difficulties among U.S. adults from 2013 to 2023, with rates nearly doubling in people under 40 and the steepest increases among lower-income and less-educated groups. Authors point to social and economic factors and call for further study.

Una forma di demenza recentemente riconosciuta, nota come LATE, sta ridefinendo la comprensione del declino cognitivo negli anziani, con diagnosi in aumento e linee guida per i medici pubblicate quest'anno. Si stima che colpisca circa un terzo delle persone di 85 anni o più e il 10% di quelle di 65 anni o più, spesso confusa con l'Alzheimer. Gli esperti sottolineano la necessità di un più ampio spettro di trattamenti per questa condizione.

Riportato dall'IA

Alzheimer's trials are shifting to a multi-target approach inspired by cancer research, even after failures with Novo Nordisk's semaglutide. Only two drugs, Eli Lilly's Kisunla and Eisai and Biogen's Leqembi, are widely approved to slow progression. This evolution treats the brain-wasting disease as a complex system, seeking new ways to halt it amid its global impact.

A new study reveals that despite guidelines, about one in four Medicare beneficiaries with dementia continue to receive brain-altering medications linked to falls and confusion. Prescribing rates have declined overall from 20% to 16% between 2013 and 2021, but those with cognitive impairment face higher risks. Researchers highlight the need for better documentation and alternatives to improve care safety.

Riportato dall'IA

Elderly and social insurance minister Anna Tenje (M) has criticized Borås for cutting back on food for the elderly while investing in the zoo. Municipal council chairman Ulf Olsson rejects the accusations, emphasizing that no savings have been made on food quality. The debate arose in a radio broadcast about rising food prices in elderly care.

Scientists at Brown University have identified a subtle brain activity pattern that can forecast Alzheimer's disease in people with mild cognitive impairment up to two and a half years in advance. Using magnetoencephalography and a custom analysis tool, the researchers detected changes in neuronal electrical signals linked to memory processing. This noninvasive approach offers a potential new biomarker for early detection.

Riportato dall'IA Verificato

A Lancet analysis estimates that nearly 800 million adults were living with chronic kidney disease in 2023—up from 378 million in 1990—with the illness now ranking ninth among global causes of death. Researchers urge earlier detection and wider access to proven treatments.

 

 

 

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta